Cuba presents advances of its vaccine candidate to PAHO/WHO

HAVANA, Cuba, Sep 3 (ACN) Finlay Vaccine Institute executives held on Wednesday an online meeting with specialists from the Pan American and World Health Organizations PAHO/WHO, where they discussed the advances of the Cuban vaccine candidate.

The meeting took place at PAHO/WHO headquarters in Cuba and also had the participation of experts from the Coalition for Epidemic Preparedness Innovations (CEPI), Carlos Fidel Martin Rodriguez, director of the National Direction of International Economic Organizations of the Ministry of Foreign Trade and Investment (Mincex by its Spanish acronym), announced on Twitter.

SOBERANA 01 has been called the phase I-II clinical trial aimed at validating the efficacy of the Cuban vaccine candidate, which began to be applied to a group of volunteers on August 24, this year.

For this purpose, volunteers from two population groups between 19 and 59 years old and another group between 60-80 years old participate in the study, to whom different doses of the drug will be applied. The research cycle comprises a 28-day period during which four blood samples are taken from the patients.

 It has been elaborated the industrial strategy that allows having the necessary millions of doses to protect Cuban population once the researches are satisfactorily concluded.

 The Finlay Institute of Vaccines has more than 30 years of experience in the development of vaccines, and the fact of having platforms developed for other epidemics, specifically for the meningitis epidemic in the 80s of the last century has allowed it to obtain these relevant results.